Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

Oncotarget

Volumn 7, Issue 21, 2016, Pages 30323-30335

  Zak, Krzysztof M ^a   Grudnik, Przemyslaw ^a   Guzik, Katarzyna ^a   Zieba, Bartosz J ^a   Musielak, Bogdan ^a   Dömling, Alexander ^b   Dubin, Grzegorz ^a   Holak, Tad A ^a,c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Checkpoint inhibitor; Immunotherapy; Small molecule; X ray structure

Indexed keywords

BMS 202; BMS 242; BMS 37; BMS 8; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INHIBITION KINETICS; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; MOLECULAR MODEL; PHARMACOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

B7-H1 ANTIGEN; CRYSTALLOGRAPHY, X-RAY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING; PROTEIN DOMAINS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84971543833     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8730     Document Type: Article

References (42)

1. Mahoney KM, Paul D, Rennert PD, Freeman JG. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Disc. 2015; 14: 561-584
2. Topalian SL, Drake CG and Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27: 450-461
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015; 348: 56-61
4. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opi Imunn. 2015; 33: 23-35
5. Mullard A. FDA approves first immunotherapy combo. Nat. Rev. Drug Discov. 2015; 14: 739
6. Ohaegbulam KC, Assal A, Lazar-Molnar, E, Yao Y, Zang XX. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med. 2015; 21: 24-33
7. Dömling A and Holak TA. Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed. 2014; 53: 2286-2288
8. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015; 23: 32-38
9. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot C, Hamid O, Bhatia S, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465
10. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, Robbins PB, Vasselli J, Ibrahim RA, Antonia SJ. J Clin Oncol. 2014; 32: 8021
11. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563-567
12. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, et al. MPDL3280A (anti-PDL1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515: 558-562
13. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20: 5064-5074
14. Sasikumar PGN, Ramachandra M, Vadlamani SK, Vemula RK, Satyam LK, Subbarao K, Shrimali RK, Kandepu S. Immunosuppression modulating compounds. Aurigene Discovery Technologies Limited. 2013; EP2585099 A2
15. Sasikumar PGN, Ramachandra M, Naremaddepalli SSS. Peptidomimetic compounds as immunomodulators. Aurigene Discovery Technologies Limited. 2013; WO2013132317 A8
16. Miller MM, Mapelli C, Allen MP, Bowsher MS, Boy KM, Gillis EP, Langley DR, Mull E, Poirier MA, Sanghvi N, Sun LQ, Tenney DJ, Yeung KS, Zhu J, et al. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PDL1 protein/protein interactions. Bristol-Myers Squibb Company. 2014; US20140294898 A1
17. Sasikumar PGN, Ramachandra M, Naremaddepalli SSS. 1,2,4-Oxadiazole Derivatives as Immunomodulators. Aurigene Discovery Technologies Limited. 2015; US20150073024 A1
18. Chupak LS, Zheng X. Compounds useful as immunomodulators. Bristol-Myers Squibb Company. 2015; WO2015034820 A1
19. Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N, Garboczi DN. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci USA. 2008; 105, 3011-3016
20. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling AS, Dubin G and Holak TA. Structure of the Complex of Human Programmed Death-1 (PD-1) and Its Ligand PD-L1. Structure. 2015; 23: 1-8
21. Shuker SB, Hajduk PJ, Meadows RP and Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996; 274: 1531-1534
22. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Mühlhahn P, Schumacher R, Hesse F, Kaluza B, et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry. 2001; 40: 336-344
23. D'Silva L, Ozdowy P, Krajewski M, Rothweiler U, Singh M, Holak TA. Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J Amer Chem Soc. 2005; 127: 13220-13226
24. Bista M, Kowalska K, Janczyk W, Dömling A and Holak TA. Robust NMR screening for lead compounds using tryptophan-containing proteins. J Amer Chem Soc 2009; 131: 7500-7501
25. Krajewski M, Rothweiler U, D'Silva L, Majumdar S, Klein C, Holak TA. An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem. 2007; 50: 4382-4387
26. Niesen FH, Berglund H and Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nature Protocols. 2007; 2: 2212-2221
27. Matulis D, Kranz JK, Salemme FR, Todd MJ. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry. 2005; 44: 5258-5266
28. de Beer TAP, Berka K, Thornton JM, Laskowski RA. PDBsum additions. Nucleic Acids Res. 2014; 42: D292-D296
29. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, Huo J, Yu C, Evans EJ, Leslie AJ, Griffiths M, Stubberfield C, Griffin R, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem. 2013; 288: 11771-11785
30. Clackson T and Wells JA. A Hot Spot of Binding Energy in a Hormone-Receptor Interface. Science. 1995; 267: 383-386
31. Arkin MR and Wells JA. Small Molecule Inhibitors of Protein-Protein Interactions: Progressing Towards the Dream. Nature Rev. Drug Disc. 2004; 3: 301-317
32. Arkin MR, Tang Y, Wells JA. Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality. Chem. Biol. 2014; 21:1102-1114
33. Chen, Y., Liu, P., Gao, F., Cheng, H., Qi, J., Gao, GF. A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell. 2010; 1: 152-160
34. Mueller U, Förster R, Hellmig M, Huschmann FU, Kastner A, Malecki P, Pühringer S, Röwer M, Sparta K, Steffien M, ühlein M, Wilk P, Weiss MS. The macromolecular crystallography beamlines at BESSY II of the Helmholtz-Zentrum Berlin: Current status and perspectives. Eur Phys J Plus. 2015; 130: 141
35. Krug M, Weiss MS, Heinemann U, Mueller U. XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS. J Appl Cryst. 2012; 45: 568-572
36. Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr. 2010; 66: 125-132
37. Evans PR. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2010; 62: 72-82
38. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read AJ. Phaser crystallographic software. J Appl Cryst. 2007; 40: 658-674
39. Emsley P, Lohkamp B, Scott WG and Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66: 486-501
40. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010; 66: 213-221
41. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011; 67: 355-367
42. Moriarty NW, Grosse-Kunstleve RW, Adams PD. Electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr D Biol Crystallogr. 2009; 65: 1074-1080